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IVanscriptional Regulation ofthe Human Calcitonin Gene:
A Progress Report
Sara Peleg,* Gilbert J. Cote,* Ronald V. Abruzzese,* and Robert F. Gagel*

We have applied DNA Iransfer techniques lo study the transcriptional regulation of the calcitonin (CT)
gene in a C-cell line (TT) derived from a human medullary thyroid carcinoma. TT cells were
transfected wilh a fusion gene conlaining the CT gene promoter and 5' -flanking DNA attached to the
promoter-less growth hormone gene (reporter). We quantitated the reporter gene produci lo monitor
transcriptional activation by the CT promoter and deletion mutants of the 5' -flanking DNA. We found
that the proximal CT promoter which includes the DNA sequence from -h I lo —129 hp upstream from
the CT transcription start site did not induce transcription in C-cells or in NIH 3T3 cells. The
attachment of additional 5'-flanking DNA, extending up to —1460 bp enhanced transcription up lo
twelvefold in TT cells bul had no effecl on transcription in 3T3 cells. Delelion ofa sequence locaied at
- /290 lo —820 bp on the CT 5' -flanking DNA abolished the transcription of the reporter gene.
Attachment of the DNA sequence located between —1333 to — 731 lo the fusion gene, containing the
CT promoter (•¥ 1 to -129) and the reporter gene, restored transcription ofthe reporter gene in TT
cells. We conclude that an enhancer ofCT transcription, which is active in C-cells bul not in 3T3 cells,
is locaied between - 1290 and - 820 of the CT 5'-flanking DNA. (Henry Ford Hosp Med J
1989:37:194-7)

ranscription of the calcitonin (CT) gene is extensive in thyroid C-cells, neuronal cells, and small numbers of cells in
normal lung, gut, and pancreas (1-3). Expression ofthe CT gene
is also common in neoplastic cells derived from these tissues
(4-8). tn cett culture systems the transcription of the CT gene
appears to be constitutive in C-cells derived from rat or human
medullary thyroid carcinoma (MTC) (9,10). This basal transcriptional activity can be upregulated by glucocorticoids (11),
cAMP (12), and phorbot esters (12,13) or down-regulated by vitamin D, (14). However, little is known about the factors which
maintain basal transcription of the CT gene and the nature of
their interaction with the other modulators of CT gene
expression.
We have recently described the employment of DNA-mediated transfection techniques in the study of cis-regutatory etements in the CT promoter and 5'-flanking DNA (15). We reported that production of growth hormone (GH) by a fusion
gene containing the metallothionein promoter, fused to the GH
gene, was augmented by the attachment of 1400 bp ofthe CT 5'ftanking DNA to the metallothionein promoter As a consequence of that addition, the fusion gene atso acquired responsiveness to cAMP and phorbot esters. The sequence anatysis of
the 1400 bp fragment reveated that it contained multiple elements which could potentially funcrion as binding sites for
cAMP response element binding (CREB) protein (16,17), API
(18) and AP2 (19), which require cAMP or phorbol esters for
their transcriptional activity. In the present study we used a series of deletion mutants of the CT 5'-flanking DNA to further
map functional cis-elements within this 5'-flanking DNA.
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Methods
Cell culture
Celts (TT) from a C-cell line derived from human MTC were
maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum. NIH 3T3 celts were grown in DMEM supplemented with 10% fetal bovine seram (11,20).
TVansfection
Twenty-four hours prior to transfection, cells were plated in
35 mm dishes at a density of 3 x tO^/dish (TT) or lOVdish (3T3)
in DMEM and 10% fetal bovine seram. Transfecrion (8 p.g plasmid DNA per dish) was by the DEAE dextran method followed
by brief treatment (1 minute) with 10% DMSO. Medium samples or cett extracts were collected five days after transfection.
GH production by the reporter gene was measured by a two-site
immunoradiometric assay as described by the manufacturer
(Nichols Institute, San Juan Capistrano, CA).
DNA cloning
Plasmid pCT GH was prepared by subcloning of a BamHtMbol fragment encoding - 129 to -F 91 of the CT gene into the
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BAMHI site located at the transcription start site of the GH
gene. Plasmid pCT GH-1 was prepared by a subcloning of the
DNA fragment encoding - 1460 to - 129 ofthe CT 5'-flanking
DNA into Hindlll-BamHI sites of pCT GH. The plasmid pCT
GH-2 was prepared by deletion of the DNA between — 1290 to
-820 of pCT GH-t by restriction digestion with BspMI. The
plasmid pCT GH-3 was prepared by a deletion of the DNA sequence between - 820 to - 429 of pCT GH-2, by a double digestion with the restriction enzymes BspMI and Apal. Plasmid
pCT GH-7 was prepared by isolation of Hindlll to Bglll fragment between - 1460 to -731 of pCT GH-t, ligation ofthe
fragment into Hindlll-BamHl sites of pCT GH and subsequent
deletion of a Hindlll-Mlul fragment tocated at position — 1460
to - 1333.
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+91
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A-1290/-429
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Results
We have recentiy reported that the attachment of a DNA fragment located at - 1460 to - 129 ofthe CT 5'-flanking DNA to
the metallothionein promoter/GH fusion gene induced a sixfold
increase in the basal transcriptional activity of the fusion gene
(15). This enhancement was observed in TT cells but not in 3T3
cells. We wished to determine if simitar results woutd be obtained when the CT promoter replaced the metallothionein promoter and, therefore, constracted plasmid pCT GH which contains the sequence between position - 129 to 3-91 of the CT
gene fused to the GH gene. We atso constracted plasmid pCT
GH-t which contains an additional fragment of CT 5'-flanking
DNA, including the sequence from - 1460 to -F 91 (Fig tA).
The transfection of pCT GH resutted in the production of low
levels of GH (0.5 ng/mL) by TT cells and by 3T3 cells (Fig IB).
Transfection of pCT GH-t into TT cells induced a twelvefold increase in GH production by TT cells, whereas the level of GH
production was unchanged in the similarly treated NIH 3T3 cells
(Fig IB). We concluded that there are DNA etements between
the - 1460 to - 129 bp of the CT 5'-flanking DNA which enhance transcription in TT but not in 3T3 cells. To nanow the
region in which the enhanced sequence(s) are located, we prepared plasmids pCT GH-2 and pCT GH-3 (Fig IA). The transcriptional activity induced by these constracts was tested in TT
and 3T3 celts. We found that removal of the sequence between
-1290 to - 820 of the CT 5'-flanking DNA (pCT GH-2) was
sufficient to abolish the transcriptional activity of the fusion
gene (Fig IB), We next wished to define whether the attachment
of the DNA sequence between - 1290 to - 820 to plasmid pCT
GH woutd be sufficient to enhance transcription, A new constract (pCT GH-7) was therefore prepared (Fig 2A), which produced identical tevels of GH as pCT GH-1 (Fig 2B), Neither
pCT GH-t nor pCT GH-7 had any significant transcriptional acfivity in 3T3 cells (Fig 2B), The lack of transcripfion in 3T3 ceUs
was not due to inefficient transfection or to the instability of GH
protein in these celts, because a controt plasmid, containing the
metallothionein promoter fused to the GH gene, produced 12 ngl
mL GH in the same experimental conditions (data not shown).
We examined the transcriptional activity of the "enhancer"containing constracts in several cell-lines which do not produce
CT (CVl, HeLa, HIT, C6 [not shown]) and found them inactive.
We, therefore, concluded that an enhancer of transcription is lo-
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Fig 1—Mapping a cis-regulatory element of transcription in the
calcitonin (CT) 5'-flanking DNA; We prepared deletion mutants
from the "wild-type" plasmid (pCT GH-1), which contains the
CT 5'-flanking DNA fused to the GH gene. Panel A shows the
position ofthe deletion in pCT GH-2 and pCT GH-3 in respect to
pCT GH-1. Panel B shows the results of a transfection experiment in which 8 |xg of either plasmid were introduced into TT
cells or NIH 3T3 cells. Media were collected flve days later and
GH levels were determined by radioimmunoassay. Shown are
the average values (nglmL) of samples obtained from three to
five separate dishes.

cated between -1290 to -820 of the CTS'-flanking DNA. The
activity of this enhancer appears to be exclusive to CT-secreting
cells.

Discussion
A region tocated within the CT 5'-flanking DNA appears to
function as an enhancer of transcription in TT cells and has been
partially mapped to between - 1290 to - 820 bp upstream from
the transcription start site of the CT gene. Enhancement of transcription by this region could occur through an interaction of a
known transcription factor (21,22) with a specific DNA sequence located within that region. Examination of the sequence
included within - 1290 to - 820 reveals that it contains three
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Fig 2—The cis-element within the calcitonin (CT) 5'-flanking
DNA operates as an enhancer of transcription; The DNA fragment, between —1333 to — 731 was attached to the transcriptionally-inactive pCT GH to produce the new plasmid pCT
GH-7. The position ofthe added sequence in respect to the unmutated plasmid pCT GH-1 is illustrated in panel A. Panel B
shows the results of the transfection experiment, performed and
analyzed as described in the legend to Fig I and in the text.
Shown are the average values (nglmL) of samples obtainedfrom
three to five separate dishes.

potential activator protein 1 (API) binding sites (18) and three
potential AP2 binding sites (19). The transcription factors binding to these DNA motifs may act independently or in concert to
augment transcription of the CT gene. However, we think it unlikely that the action of API and/or AP2 at that region is responsible for the results described here. When constracts containing
the putative API and AP2 sites were transfected into HeLa celts,
which are known to express both API and AP2 (23,24), they
failed to enhance transcription. We believe, therefore, that the
possibility exists that another previously undescribed DNA
motif is located between - 1290 and - 820. Additional studies
are required to prove this point, de Bustros et at (25) have re-
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cently presented data suggesting that this same region ofthe CT
5'-flanking DNA is active as an enhancer of transcription in a
lung carcinoma cett tine which expresses the CT gene. These
findings raise the possibility that utilization of the enhancer tocated between —1290 and —820 may resutt from ectopic expression (or function) of a transcription factor in both the transformed C-cells and in the lung carcinoma cells. Altematively,
this transcription factor may be normally functional in C-cells
but abenantly produced and function in the lung carcinoma cell
line.
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